PLYMOUTH, Michigan – June 8, 2017 – Hospitals across the country have the same goal: providing the best care for their patients. With increased accessibility to 3D printed anatomical models, surgical teams are now able to develop patient-specific surgical plans prior to entering the operating room, resulting in a positive impact on patient care and the hospital’s business. With these models and plans, surgeons are able to prepare for and treat more difficult cases, such as complex heart conditions or tumors in proximity to vital organs, reducing operating room times as well as the the chances of unforeseen complications.
As hospitals and surgeons continue to see the value and discover new applications for 3D printed models, more are bringing 3D printing operations to a point of care setting. To address the growing demand for 3D printing, Leuven, Belgium-based 3D printing solutions provider Materialise will host a 3D Printing in Medicine Course June 11-13, 2017 at the Inn at St. John’s in Plymouth, Michigan.
During the event, attendees will learn how to develop in-house 3D printing programs and how this technology has been implemented in the medical field to revolutionize patient care. Attendees will also have an opportunity to tour Materialise’s North American headquarters in Plymouth, Michigan, and will receive hands-on training on Materialise 3D printing software, which serves as the backbone of 3D printing in the healthcare industry.
“This event will demonstrate the benefits that esteemed medical institutions such as the Mayo Clinic, Boston Children’s Hospital and The Ottawa Hospital have experienced since implementing in-house 3D printing solutions,” said Bryan Crutchfield, vice president and general manager of Materialise North America. “Those attending will learn how to develop in-house 3D printing programs and how this technology has been implemented in the medical field to revolutionize patient care.”
Frank Rybicki, MD, Ph.D., of The Ottawa Hospital will deliver the keynote speech on June 11. His discussion will cover the past, present and future of 3D printing in hospitals and how bringing these processes in-house, reduces costs and delivers higher quality patient care faster than ever.
On June 12, attendees will hear from medical professionals about specific applications of 3D printing in healthcare, including:
- Dee Dee Wang, M.D., a cardiologist with Henry Ford Health Systems, will discuss how 3D printing enables innovative cardiac interventions
- Shi-Joon Yoo, M.D., Ph.D., a cardiac radiologist and head of the Division of Cardiac Imaging with the Hospital for Sick Children, will discuss the impact of 3D printing in Congenital Heart Disease
- Nicole Wake, Ph.D., of New York University, will discuss new uses of 3D printing in urologic procedures
Materialise has leveraged more than 27 years of experience in the 3D printing industry to develop software and services that act as the backbone of medical 3D printing solutions. The company works with medical professionals to help them efficiently develop and implement solutions to improve access to the cost-saving, patient specific benefits of 3D printing.
About Materialise
Materialise incorporates more than 27 years of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of 3D printing technologies. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines the largest group of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.
Cautionary Statement on Forward-Looking Statements
Some of the statements in this press release are “forward-looking” and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements relating to, among other things, our planned commercialization efforts and regulatory approvals of our technologies as well as the success thereof and our research and development projects. These forward-looking statements are based upon the expectations of management under current assumptions at the time of this press release. We caution you that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control that may cause our actual results to differ materially from our expectations. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this presentation as a result of new information, future events or otherwise, unless we have obligations under the federal securities laws to update and disclose material developments related to previously disclosed information.
